Stock Scorecard

Stock Summary for Organon & Company (OGN) - $9.96 as of 7/4/2025 1:49:25 AM EST

Total Score

12 out of 30

Safety Score

56 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OGN (56 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 10
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 10
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for OGN

Organon ( OGN ) Stock Dips While Market Gains: Key Facts 7/3/2025 9:50:00 PM
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN - Organon ( NYSE:OGN ) 7/3/2025 8:29:00 PM
Deadline Alert: Organon & Co. ( OGN ) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Organon ( NYSE:OGN ) 7/3/2025 5:12:00 PM
OGN vs. MEDP: Which Stock Is the Better Value Option? 7/3/2025 3:40:00 PM
Karolinska Development receives update from Organon concerning OG-6219 7/3/2025 5:00:00 AM
ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN - Organon ( NYSE:OGN ) 7/3/2025 2:13:00 AM
OGN CLASS ACTION: A Class Action was filed against Organon & Co. for Securities Fraud -- Contact BFA Law by July 22 Legal Deadline ( NYSE:OGN ) - Organon ( NYSE:OGN ) 7/2/2025 12:48:00 PM
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN - Organon ( NYSE:OGN ) 7/2/2025 2:17:00 AM
ROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN - Organon ( NYSE:OGN ) 7/1/2025 4:14:00 PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN - Organon ( NYSE:OGN ) 7/1/2025 2:00:00 PM

Financial Details for OGN

Company Overview
Ticker OGN
Company Name Organon & Company
Country USA
Description Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 9.96
Price 4 Years Ago 25.49
Last Day Price Updated 7/4/2025 1:49:25 AM EST
Last Day Volume 2,377,417
Average Daily Volume 4,377,866
52-Week High 22.24
52-Week Low 8.01
Last Price to 52 Week Low 24.34%

Valuation Measures
Trailing PE 3.52
Industry PE 21.93
Sector PE 40.90
5-Year Average PE 6.03
Free Cash Flow Ratio 4.74
Industry Free Cash Flow Ratio 17.71
Sector Free Cash Flow Ratio 32.91
Current Ratio Most Recent Quarter 1.67
Total Cash Per Share 2.10
Book Value Per Share Most Recent Quarter 2.10
Price to Book Ratio 4.87
Industry Price to Book Ratio 34.53
Sector Price to Book Ratio 30.76
Price to Sales Ratio Twelve Trailing Months 0.42
Industry Price to Sales Ratio Twelve Trailing Months 121.97
Sector Price to Sales Ratio Twelve Trailing Months 35.60
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics
Total Shares Outstanding 259,956,000
Market Capitalization 2,589,161,760
Institutional Ownership 80.89%

Dividends
Ex-Dividend Date 5/12/2025
Previous Dividend Amount 0.2800
Current Dividend Amount 0.0200
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 0.86
Trailing Annual Dividend Yield 8.47%
Forward Annual Dividend Rate 0.08
Forward Annual Dividend Yield 0.79%
5-Year Dividend Payments Count 16
3-Year Average Dividend Yield 7.66%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage -92.86%
3-Year Dividend Growth Rate Percentage -73.27%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio 29.86%

Income Statement
Quarterly Earnings Growth YOY -57.70%
Annual Earnings Growth -15.54%
Reported EPS 12 Trailing Months 2.88
Reported EPS Past Year 1.02
Reported EPS Prior Year 4.11
Net Income Twelve Trailing Months 750,000,000
Net Income Past Year 864,000,000
Net Income Prior Year 1,023,000,000
Quarterly Revenue Growth YOY -6.70%
5-Year Revenue Growth -3.81%
Operating Margin Twelve Trailing Months 21.50%

Balance Sheet
Total Cash Most Recent Quarter 547,000,000
Total Cash Past Year 675,000,000
Total Cash Prior Year 693,000,000
Net Cash Position Most Recent Quarter -8,389,000,000
Net Cash Position Past Year -8,185,000,000
Long Term Debt Past Year 8,860,000,000
Long Term Debt Prior Year 8,751,000,000
Total Debt Most Recent Quarter 8,936,000,000
Equity to Debt Ratio Past Year 0.05
Equity to Debt Ratio Most Recent Quarter 0.06
Total Stockholder Equity Past Year 472,000,000
Total Stockholder Equity Prior Year -70,000,000
Total Stockholder Equity Most Recent Quarter 542,000,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 651,000,000
Free Cash Flow Per Share Twelve Trailing Months 2.50
Free Cash Flow Past Year 764,000,000
Free Cash Flow Prior Year 538,000,000

Options
Put/Call Ratio 1.62
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.05
MACD Signal -0.02
20-Day Bollinger Lower Band 6.73
20-Day Bollinger Middle Band 11.88
20-Day Bollinger Upper Band 17.02
Beta 0.55
RSI 54.71
50-Day SMA 15.26
150-Day SMA 17.80
200-Day SMA 20.44

System
Modified 7/3/2025 6:56:38 AM EST